Abstract Released for E7386, Created Through Collaborative Research Between Eisai and PRISM TOKYO, Sept. 8, 2024 /PRNewswire/ — PRISM BioLab, Co. Ltd. (“PRISM”), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.